
Publisher's PDF, also known as Version of record
License (if available): CC BY
Link to published version (if available): 10.1016/j.ejor.2020.05.030

Link to publication record in Explore Bristol Research
PDF-document

This is the final published version of the article (version of record). It first appeared online via Elsevier at https://doi.org/10.1016/j.ejor.2020.05.030. Please refer to any applicable terms of use of the publisher.

**University of Bristol - Explore Bristol Research**

**General rights**

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
Assessment of a causal relationship between body mass index and atopic dermatitis

To the Editor:

Atopic dermatitis (AD) is an itchy, inflammatory skin condition associated with multiple comorbidities. Observational epidemiology suggests an increased prevalence of obesity in patients with AD, but (1) whether there is a causal effect and (2) whether obesity leads to AD or vice versa remain unclear. Genetic predisposition to obesity has been shown to promote psoriasis, but dermatologic disorders can also lead to reduced participation in physical activity, resulting in weight gain. We aimed to investigate evidence of causality in the association of AD with elevated body mass index (BMI).

We meta-analyzed 33 published studies examining the association between obesity or elevated BMI and AD to summarize available observational data (see Fig E1 in this article’s Online Repository at www.jacionline.org). The odds ratio (OR) for AD in overweight individuals was 1.05 (95% CI = 0.94-1.19) in adults (n = 51,008) and 1.08 (95% CI = 1.00-1.16) in children (n = 506,202) (see Fig E2 in this article’s Online Repository at www.jacionline.org). For obese individuals, the OR for having AD was 1.19 (95% CI = 0.95-1.49) in adults (n = 1,400,679) and 1.20 (95% CI = 1.11-1.30) in children (n = 796,514) (see Fig E3 in this article’s Online Repository at www.jacionline.org). We extended the observational analysis by using 2 large population-based studies from the United Kingdom and Norway2,3 (for details, see the Online Repository and Tables E1-E4). Among overweight individuals (BMI of 25-30 kg/m²), the OR of AD was 1.02 for each 1-kg/m² increase in BMI (95% CI = 1.00-1.04; P = .07; 4,820 cases and 130,776 controls); a similar estimate was found among obese individuals (BMI >30 kg/m²) (ie, OR = 1.02 (95% CI = 1.01-1.03; P = 3.3 × 10⁻⁴) in a sample of 2,741 cases and 73,907 controls) (see Fig E4 in this article’s Online Repository at www.jacionline.org).

Observational epidemiology has several limitations, including bias from confounding and reverse causation; this restricts its utility for causal inference. However, causality and the direction of effect can be investigated by mendelian randomization (MR). MR uses genetic variants as a proxy for the exposure (eg, BMI) to estimate the effect on an outcome (eg, AD). Genetic variants are randomly allocated at fertilization, therefore avoiding confounding; they are not affected by outcomes later in life, thus avoiding reverse causation. Genome-wide association studies (GWASs) have identified single-nucleotide polymorphisms (SNPs) associated with BMI (≤941 loci⁴⁻⁵) and AD (24 loci in European populations⁶). These SNPs can be combined into a genetic risk score (GRS) or “genetic instrument” that acts as a proxy for the specified trait during MR.

We conducted MR analysis by using data from the largest population-based studies in the United Kingdom (UK Biobank) and Norway (Nord-Trøndelag Health Study, Norway) [HUNT, 2006-08] along with the largest published GWASs for BMI⁴⁻⁵ and AD⁶ to date, representing a total of 742,611 individuals (see Table E5 in this article’s Online Repository at www.jacionline.org). One-sample MR was performed in the UK Biobank and HUNT data sets with the individuals’ BMI SNPs, measured BMI, and AD status. Two-sample MR using published GWAS data⁷⁻⁹ was performed and meta-analyzed with the 1-sample estimate to obtain an overall causal estimate. Similarly, reverse MR was conducted to investigate the effect of AD genetic risk on BMI. Methodologic details and sensitivity analysis are described in the Online Repository, including Fig E5.

The BMI GRS was strongly associated with BMI in both the UK Biobank and HUNT data sets (see Figs E6 and E7 in this article’s Online Repository at www.jacionline.org), supporting its use as a genetic instrument. Potential confounders of the GRS-BMI association were detected (see Figs E6-E9), but the magnitudes were minimal in comparison with the strength of association with BMI. Similarly, the AD GRS was a good predictor of AD in both the UK Biobank (OR = 1.26 [95% CI = 1.23-1.28]; F-statistic = 2036; R² = 0.7%) and HUNT (OR = 1.15 [95% CI = 1.11-1.21]; F-statistic = 97; R² = 0.4%) data sets, despite lacking an FLG null genotype (R501X/rs61816761), which is known to show strong association with AD.

Meta-analyzed 1- and 2-sample MRs show evidence of a small causal effect of higher BMI increasing the risk of AD (OR = 1.02 [95% CI = 1.00-1.04]; P = .03) (Fig 1). This represents an increase in AD risk by approximately 2% for each 1-kg/m² increase in BMI, which is remarkably similar to the observational estimate (see Figs E2 and E3 in the Online Repository). Importantly, sensitivity analyses showed little evidence of pleiotropy (for details, see the Sensitivity Analysis section, Table E6, Fig E10, and Results sections of the Online Repository at www.jacionline.org). The difference was little evidence of pleiotropy but modest heterogeneity among the individual SNP effect estimates (see Figs E6-E9 and Table E7 in this article’s Online Repository at www.jacionline.org), supporting its use as a genetic instrument.

In the reverse direction, meta-analysis gave weak evidence of a very small causal effect (Fig 2): a 0.03-kg/m² change in BMI per doubling odds of AD (95% CI = -0.02 to 0.08; P = .24). There was little evidence of pleiotropy but modest heterogeneity among the individual SNP effect estimates (see Fig E12 and Table E7 in this article’s Online Repository at www.jacionline.org). The difference in BMI between patients with AD and controls estimated in 1-sample MR (0.15 kg/m², 95% CI -1.97 to 2.27) was small compared with observational estimates (see Tables E1 and E2), indicating that the association is mainly explained by the causal effect of BMI on AD.

The association of obesity with cardiometabolic disease and systemic inflammation is now well recognized, and clinical guidelines recommend screening patients with psoriasis for obesity. The presence of a causal effect and the direction of effect are both clinically relevant, to define a primary target (ie, obesity) for intervention. Our MR analysis shows evidence that higher
BMI increases the risk of AD (ie, a 2% increase in disease risk for each 1-kg/m² increase in BMI). Conversely, there was no strong evidence of a causal effect of AD genetic risk on BMI; the estimate of 0.03 kg/m² suggests that genetic risk for AD has little meaningful influence on an individual’s BMI. These findings may be compared with the causal effect of BMI on psoriasis and lack of effect of psoriasis genetic risk on BMI. The effect of BMI on AD is more modest than the effect size observed in psoriasis, but the high prevalence of obesity (in more than one-third of US adults) and AD (≤10% of adults) demonstrate the potential importance of this causal effect on a population scale.

The molecular mechanisms by which obesity contributes to skin inflammation remain unclear. Excess adipose tissue secretes proinflammatory cytokines and hormones, and atopic inflammation may be promoted by disruption of the epidermal barrier in obese individuals. Changes in the adipocytes and lymphatic vessels may also contribute to obesity-related skin inflammation. Research to define mechanisms underlying the causal relationship demonstrated by MR may identify novel therapeutic targets.

Our MR analyses have various strengths as well as weaknesses. The large sample size is powerful, and the genetic instruments are strong. The 2-sample analysis included an overlap of data sources (from the HUNT study), which has the potential to bias the causal estimate, but this bias would be in the direction of the null. There is the possibility of misclassification of AD, and because AD often shows remission in childhood, this phenotype may be particularly susceptible to recall bias in adult studies; however, this would likely drive any estimate toward the null. It is also important to note that the MR methodology applied here does not define temporal relationship. Genetic risk has a lifetime effect and therefore predates disease onset, but a causal effect determined by MR does not rely on obesity occurring before the onset of AD. However, when we attempted to mitigate this issue by repeating the MR analyses using SNPs that are strongly associated with childhood BMI, a causal estimate with the same direction of effect was obtained (OR = 1.04; 95% CI = 1.01-1.07; P = .01). Nevertheless, replication of these analyses within pediatric cohorts with large sample sizes would be valuable future work.

In conclusion, we have found evidence of a small but potentially important causal effect of BMI on AD. Clinical trials have shown that interventions to promote weight loss can lead to improvement in psoriasis, but this approach has not been tested in AD. The results of our study provide support for the investigation of obesity management strategies and/or targeting of the adipocyte-keratinocyte cross-talk as therapeutic opportunities for AD. This may contribute to the prevention of AD, as well as to a reduction in the population prevalence of this chronic disease.
This research was conducted by using data from the UK Biobank Resource (application number 10074) and the Nord-Trøndelag Health Study (the HUNT Study). Details of patient and public involvement in the UK Biobank are available online (http://www.ukbiobank.ac.uk/about-biobank-uk/) and https://www.ukbiobank.ac.uk/wp-content/uploads/2011/07/Summary-EGF-consultation.pdf?phpMyAdmin=trimKOY3dyjqQfjgJ%2CIaizkMhEnx6). The UK Biobank data set used to conduct the research in this article is available via application directly to the UK Biobank. Applications are assessed for meeting the required criteria for access, including legal and ethics standards. More information regarding data access can be found at the following website: http://www.ukbiobank.ac.uk/scientists-3/. Data from the HUNT Study used in research projects will, when reasonably requested by others, be made available on request to the HUNT Data Access Committee (hunt@medisin.ntnu.no). The HUNT data access information (available at: http://www.ntnu.edu/hunt/data) describes in detail the policy regarding data availability. No patients were specifically involved in setting the research question or the outcome measures, nor were they involved in developing plans for recruitment, design, or implementation of this study. No patients were asked to advise on interpretation or writing up of results. There are no specific plans to disseminate the results of the research study to participants, but the UK Biobank and the HUNT Study disseminate key findings from projects on their websites. The HUNT Study is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology), Nord-Trøndelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. We acknowledge the permission of the EAGLE consortium (including 23andMe) to use results from their previous GWAS of AD (Paternoster et al.).

Ashley Budu-Aggrey, PhDa,b
Sarah H. Watkins, PhDa,b
Ben Brumpton, PhDc,d
Mari Løset, MD, PhDc,e
Jess Tyrrell, PhD
Ellen H. Modalal, MD, Phyx,h
Gunnhild Aberg Vie, PhDb
Tom Palmer, PhDh
Lars G. Frithsche, Phd
Jonas Bille Nielsen, MD, Phdy
Pål Richard Romundstad, PhDk
George Davey Smith, MD, DSc,b
Bjørn Olav Asvold, MD, Phdz
Lavinia Paternoster, Phdz
Sara J. Brown, FRCPFa

From a the Medical Research Council Integrative Epidemiology Unit and b Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom; c the K.G. Jebsen Center for Genetic Epidemiology, d the Department of Public Health and Nursing, and e the Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway; f the Department of Thoracic and Occupational Medicine, g the Department of Endocrinology, St Olav’s Hospital, h the Department of Dermatology, Institute of Biomedical and Clinical Science, University of Exeter Medical School, Royal Devon and Exeter Hospital, Exeter, United Kingdom; i the Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Mich; j the Skin Research Group, School of Medicine, University of Dundee, Dundee, United Kingdom; and k the Department of Dermatology, Ninewells Hospital and Medical School, Dundee, United Kingdom. E-mail: s.j.brown@dundee.ac.uk.

REFERENCES